




Altitud	de levels
	tion of Altitude Proposed ch and B. Saltin (2008)
Definition	Altitude, meters above sea leve
Near sea level	0-500
Low altitude	500-2000
Moderate altitude	2000-3000
High altitude	3000–5000
Extreme altitude	Above 5000












		Table 3	Effects of hy	poxic trainin	g on sea level er	idurance perfor	mance	
C.A.R.	<ul> <li>Controversial results</li> </ul>	Hypoxic stimulus	Altitude (m)	Exposure time (days)	Time tested after altitude (days)	Submaximal improvement	Change inVo <sub>2</sub> мах (%)	Control group
	results		_	$\sim$	Potentiating eff	ects		
		CH <sup>42</sup>	1300-2500	28	1	Yes†	+4†	No
m		CH <sup>41</sup> CH <sup>44</sup>	1900 2100-2700	21 14	1/14 2	Yes† Yes†	NS/NS NS	No No
ACD /		CH45	2300	23	3/21	Yest	+8†/+10†	No
		CH**	2500	28	7	ND	+6†	No
		1H47	3049-4268	23	3-4	Yest	NS	No
		8H**	3800	35	14	ND	+14†	No
		IH*	4020	21/28	1	Yes†	+8‡/+26‡	No
		CH50	1250-2500	28	7	Yest	+4†	Yes
		IH <sup>51</sup>	2300	21-28	1	Yes†	NS	Yes
		IH <sup>52</sup>	2300	28	1-2	Yes†	ND	Yes
184		IH33	4000	70	1	Yes	NS	Yes
					No potentiating		210	N.
J / A		CH <sup>45</sup>	2300 1695-2700	14 7	1	No ND	NS NS	No No
IERIA DIEVADA		CH <sup>34</sup> CH <sup>35</sup>		20	4 4/22	ND	NS +6/+9*	No
nennes mevesters		CH <sup>36</sup>	2240 2300	42	4/22	No	NS	No
		CH <sup>57</sup>	2300	70	5	ND	NS	No
		CH <sup>58</sup>	2800	10	2-4	No	+7*	No
		CH <sup>59</sup>	3090	17	1	ND	NS	No
111 200		CH <sup>60</sup>	3110	21	7	ND	-5*	No
		CH <sup>61</sup>	4000	48-63	2-15	No	NS	No
1 4 M		IH <sup>62</sup>	4000	21	1	ND	NS	No
		CH38	2000	14	6/12	ND	NS/NS	Yes
17-14		CH <sup>63</sup>	1600-1800	18-28	7	ND	NS	Yes
		CH <sup>64</sup>	1640	28	20	No	NS	Yes
DEPRINTS, DUE VISIDAS,		CH <sup>65</sup>	1700-2000	28	7	No	NS	Yes
		CH <sup>66</sup>	2300	21	1	No	NS +17.5*	Yes Yes
		IH <sup>67</sup> IH <sup>67</sup>	2250 3450	28 28	1	ND ND	+17.5*	Yes
		IH <sup>68</sup>	2500	28	1	No	NS	Yes
171		IH**	2500	28 35	1	ND	NS	Yes
		CH <sup>70</sup>	2600	11	i	ND	NS	Yes
		IH <sup>71</sup>	3100	19	6	No	NS	Yes
		IH72	3345	42	1	ND	NS	Yes
J /		IH73	4020	15	1	ND	NS	Yes
IERRA LIEVASA		IH <sup>74</sup>	4100-5700	21	1	ND	NS	Yes
n-menn-verber		CH75	4300	28	1-5	ND	NS	Yes
Moree	Bailey DM and , Davies B. BJSM 1997.	* Level o † Signific ‡ Signific	f significance n antly different antly different	ot reported . from pre-altit from pre-altit	tent hypobaria; l tude value (P<0. tude value (P<0. re-altitude value	05). 01).		


Study	Subjects	Sample size <sup>a</sup>	Design	Competit-	Training phase	Hypoxic (h/d) <sup>b</sup>	Exposure/ intervention	Altitude level (m) <sup>d</sup>	Hypox device
						(	days°		
Live-high train-high									
Bailey et al.[29]	Runners	8M, 2F; 14M, 5F	с	Elite	?	24	28	1640	
	Runners	9M, 5F; 6M, 3F	С	Elite	?	24	28	1750	
Burtscher et al.[30]	Runners	10M; 12M	С	Subelite	?	24	12	2315	
Friedmann et al. <sup>[31]</sup>	Boxers +Fe <sup>e</sup>	9M	U	Subelite	Off-season	24	18	1800	
	Boxers Fe <sup>e</sup>	7M	U	Subelite	Off-season	24	18	1800	
Gore et al.[32]	Cyclists	8M	U U	Elite	?	24	31	2690	
Ingjer and Myhre <sup>[30]</sup> Jensen et al. <sup>[34]</sup>	Skiers Bowers	7M; 7M 9M; 9M	c	Elite	Competitive Competitive	24 24	21 21	1900 1822	
Levine and Stray-Gundersen <sup>[35]</sup>	Runners	9M; 9M 10?	U	Subelite	2 Competitive	24	21 28	1822	
Levine and Stray-Gundersen	Runners	9?	U	Subelite	2	24	28	2500	
Levine and Stray-Gundersen <sup>[2]</sup>	Runners	97 9M, 4F; 9M, 4F	c	Subelite	r Competitive	24	28	2500	
Mivashita et al. <sup>[36]</sup>	Swimmers	9m, 4F, 9m, 4F 12M, 8F	U	Elite	Competitive	24	20	2300	
Pyne <sup>[37]</sup>	Swimmers	14M, 8F	Ŭ	Eite	Competitive	24	21	2102	
Rusko et al. <sup>[38]</sup>	Skiers	14M; 7M	č	Elite	?	24	22	1700	
Saunders et al. <sup>[39]</sup>	Runners	10M; 13M	č	Eite	2	24	20	1750	
Svedenhag and Saltin <sup>[40]</sup>	Bunners	5M; 4M, 2F	c	Elite	?	24	14	2000	
Svedenhag et al.[41]	Skiers	5M, 2F	U	Elite	?	24	30	1900	
Live-high train-low									
Dehnert et al.[42]	Triathletes	6?; 10?	с	Subelite	?	~18-24	13	1956/800	
Levine and Stray-Gundersen <sup>[2]</sup>	Runners	9M, 4F; 9M, 4F	с	Subelite	Competitive	~18-24	28	2500/1200	
Stray-Gundersen and Levine <sup>[43]</sup>	Runners	6?	U	Subelite	?	~18-24	28	2500/1200	
Stray-Gundersen et al.[8]	Runners	8F, 14M	U	Elite	Competitive	~18-24	27	2500/1200	
Wehrlin et al.[44]	Orienteers	5M, 5F	U	Elite	Pre-season	~18-24	24	2456/1000	
Witkowski et al.[45]	Runners	8M, 4F	U	Subelite	?	~18-24	28	1780/1250	
	Runners	8M, 4F	U	Subelite	?	~18-24	28	2085/1250	
	Runners	8M, 4F	U	Subelite	?	~18-24	28	2454/1250	
	Runners	8M, 4F	U	Subelite	?	~18-24	28	2805/1250	


C.A.R.	<ul> <li>Controversial</li> </ul>	results		
	Effect	Natural altitud	de protocols	Artificial altitude protocols
		live-high train-high	live-high train-low	live-high 8–18 h/d, continuous, train-low
	Effect of mean protocol <sup>a</sup> (%);	±90% CL <sup>b</sup>		
	Elite	(1.6; ±2.7)	4.0; ±3.7	(0.6; ±2.0)
	Subelite	(0.9; ±3.4)	4.2; ±2.9	1.4; ±2.0
	Effect of enhanced protocol <sup>c</sup> (			
	Elite	5.2; ±4.1	4.3; ±4.1	(4.0; ±5.5)
	Subelite	4.5; ±4.1	4.6; ±3.3	4.8; ±5.3
	Bonetti DL and Hopkins WG.			

ALTITUDE TRAINING	
"Elite athletes have used altitude/hypoxic training for several years. Although the efficacy of altitude/ hypoxic training relative sea-level performance remains controversial from a research perspective, athletes continue to use it in preparation for elite le competition".	
WILBER, R. L. Application of Altitude/Hypoxic Training by Elite Athletes. Med. Sci. Sports Exerc., Vo No. 9, pp. 1610–1624, 2007	ol. 39,
"Enhancing protocols by appropriate manipulation of st characteristics produced clear effects with all protocols (3.5–6. in subelite athletes, but only with LHTH (5.2%) and LHTL (4.3% elite athletes.	8%) 6) in
BONETTI DL, Hopkins WG. Sea-level exercise performance following adaptation to hypoxia: a meta-analysis. Spor 2009;39(2):107-27.	ts Med.






































AMS							
			1				
	su	% bjects			LL	score	
LL1 - headache	8	39.65		2,5			
LL2 - GI symptoms	7	2.41		2 - 2	,01*	.81	
LL3 - fatigue / weakness		3.10		1.5 -			45
LL4 - dizziness		68.96				*	~
LL5 - difficulty sleeping		32.76		1 -			
Clinical symp		100	itudo	e train		2 semana3	sem
<u>Clinical symp</u>	otons	100		0 semana	ing	2 semana3	sem
Clinical symp	otons	in all	Lo	e train	<b>tota</b>		sem
Clinical symp	<b>otons</b> Hi	<u>in al</u>	Lo	e train	Total	%	p
Clinical symp Periodo altura (3 sem.) Síntomas Generales	Hi n 5	100 5 in ali % 17,24	Lo n 2	0	Total 7	% 17,5	p 1
Clinical symp Periodo altura (3 sem.) Síntomas Generales Respiratorios	0tons	100 5 in ali 17,24 34,48	Lo n 2 3	0	Total n 7 13	% 17,5 32,5	p 1 1
Clinical symp Periodo altura (3 sem.) Síntomas Generales Respiratorios Digestivos	Hi n 5 10 5	% 17,24 34,48 17,24	Lo n 2 3 2	% 18,18 27,27 18,18	Total n 7 13 7	% 17,5 32,5 17,5	p 1
Clinical symp Periodo altura (3 sem.) Síntomas Generales Respiratorios	0tons	100 5 in ali 17,24 34,48	Lo n 2 3	0	Total n 7 13	% 17,5 32,5	p 1 1

